The Atrial Fibrillation Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Atrial Fibrillation Market:
https://www.thebusinessresearchcompany.com/report/atrial-fibrillation-global-market-report
According to The Business Research Company’s Atrial Fibrillation Global Market
Report 2024, The atrial fibrillation market size has grown rapidly in recent
years. It will grow from $12.02 billion in 2023 to $13.47 billion in 2024 at a
compound annual growth rate (CAGR) of 12.1%.
The growth in the historic period
can be attributed to increasing
awareness and screening programs, technological innovations in treatment,
increasing healthcare expenditure, clinical research and drug development,
genetic predisposition..
The atrial fibrillation market size is expected to see rapid growth in the next
few years. It will grow to $21.66 billion in 2028 at a compound annual growth
rate (CAGR) of 12.6%. The growth in the
forecast period can be attributed to focus on stroke prevention, patient and
physician education programs, global initiatives for cardiovascular health,
increasing electrophysiology procedures, customization of treatment plans,
government initiatives for cardiovascular disease prevention.. Major trends in
the forecast period include advancements in diagnostic technologies, rise in
the incidence of atrial fibrillation, advancements in catheter ablation
techniques, emergence of novel oral anticoagulants (noacs), integration of
wearable technologies for monitoring, expanding role of telemedicine in af
management, advancements in implantable devices..
The increase in the geriatric population is expected to drive the atrial
fibrillation market forward. The geriatric population refers to adults 65 and
older who are more likely to fall due to various factors, such as postural
hypotension and balance or gait problems. Age factor and conduction
disturbances are present on the surface electrocardiogram before AF onset in
most geriatric patients. For instance, in October 2022, according to the World
Health Organization, a Switzerland-based specialized agency of the United
Nations responsible for international public health, six people in the world
will be aged 60 years or older by 2030. At this point, there will be 1.4
billion people, up from 1 billion in 2020, who are 60 years of age or older.
The number of individuals 60 and older in the world will double (to 2.1
billion) by the year 2050. Between 2020 and 2050, there will be 426 million
more people who are 80 years of age or older than there are today. Therefore, the growing geriatric population
is driving the growth of the atrial fibrillation market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=8007&type=smp
The atrial fibrillation market covered in this report is segmented –
1) By Type: Surgical, Non-Surgical
2) By Technology: Radiofrequency, Laser, Cryotherapy, Other Technologies
3) By Treatment Type: Pharmacological Treatment, Non-pharmacological Treatment,
Maze Surgery, Electric Cardioversion
4) By End User: Hospitals, Electrophysiology Labs, Ambulatory Surgical Centers
Major companies in the atrial fibrillation market are launching innovative products and solutions such as
patient-centric clinical decision support tools to strengthen their position in
the market. Clinical decision support tools (CDST) are software or electronic
systems designed to assist healthcare professionals in making informed and
timely decisions about patient care. These tools are developed to integrate
relevant clinical information from various sources. For instance, in August
2023, GE HealthCare, a US-based multinational medical technology company
launched the CardioVisio, a patient-centered clinical decision support tool to
help doctors drive evidence-based clinical decision support guided by current
atrial fibrillation guidelines and visualize longitudinal data from various
data sources relevant for illness progression.
CardioVisio for atrial fibrillation, can assist cardiologists with in
streamlining clinician image interpretation and to provide a view of the
history of the patient’s heart as well as their healthcare journey, including
previous diagnoses, prescribed medications, interventions, and comorbidities.
The atrial fibrillation market report table of contents includes:
1. Executive Summary
2. Atrial
Fibrillation Market Characteristics
3. Atrial
Fibrillation Market Trends And Strategies
4. Atrial
Fibrillation Market - Macro Economic Scenario
5. Global
Atrial Fibrillation Market Size and Growth
.
31. Global Atrial Fibrillation Market Competitive Benchmarking
32. Global
Atrial Fibrillation Market Competitive Dashboard
33. Key
Mergers And Acquisitions In The Atrial Fibrillation Market
34. Atrial
Fibrillation Market Future Outlook and Potential Analysis
35.
Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment